Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 870 across all filing types
Latest filing 2024-06-11 Annual Report
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
西部证券股份有限公司关于圣湘生物科技股份有限公司2023年年度报告信息披露监管问询函回复的核查意见
Annual Report Classification · 95% confidence The document is a detailed response from a securities company to a regulatory inquiry regarding the 2023 annual report of Shengxiang Biotechnology Co., Ltd. It contains extensive financial data, analysis of business performance, receivables, inventory, and R&D expenditures for the fiscal year 2023. The document references the 2023 annual report multiple times and provides in-depth financial and operational explanations, indicating it is part of the annual reporting process. The length (15,000 characters) and detailed financial content confirm it is not a brief announcement or certification but a substantive report. Therefore, this document is best classified as an Annual Report (10-K) type filing. FY 2023
2024-06-11 Chinese
圣湘生物科技股份有限公司关于2023年年度报告信息披露监管问询函的回复公告
Audit Report / Information Classification · 95% confidence The document is a detailed reply to a regulatory inquiry regarding the company's 2023 Annual Report. It contains extensive financial data, analysis of revenue, receivables, inventory, R&D expenditures, and comparisons with industry peers. The document references the 2023 Annual Report multiple times and provides supplementary explanations and clarifications on the financial figures disclosed therein. It is not merely an announcement or a brief summary but a comprehensive regulatory response with substantive financial content. Therefore, it is classified as an Audit Report / Information (AR), which includes standalone audit reports and regulatory inquiry responses related to annual reports but distinct from the full Annual Report itself. FY 2023
2024-06-07 Chinese
圣湘生物科技股份有限公司关于自愿披露相关产品取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the voluntary disclosure of obtaining a medical device registration certificate for a specific product. It details the product registration information, its intended use, impact on the company, and risk warnings. There are no financial statements, earnings data, or detailed financial analysis. The document is relatively short (1542 characters) and serves as a regulatory announcement about product certification rather than a financial report or management discussion. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit other specific categories.
2024-06-06 Chinese
湖南启元律师事务所关于圣湘生物科技股份有限公司差异化权益分派事项之法律意见书
Regulatory Filings
2024-06-03 Chinese
圣湘生物科技股份有限公司2023年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement regarding the implementation of the 2023 annual dividend distribution by the company 圣湘生物科技股份有限公司. It details the dividend amount per share, relevant dates (record date, ex-dividend date, payment date), the approval of the dividend plan at the 2024 shareholders meeting, tax treatment for different shareholders, and instructions for dividend payment. The document is relatively short (3270 characters) and focuses solely on dividend distribution details without containing full financial statements or comprehensive financial performance data. This matches the definition of a Notice of Dividend Amount (DIV), which announces dividend amounts, payment dates, and details for shareholders.
2024-06-03 Chinese
圣湘生物科技股份有限公司关于参加2023年度科创板集体业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the company's participation in the 2023 annual Sci-Tech Innovation Board collective performance explanation meeting. It details the meeting time, location, participants, and how investors can ask questions and attend. It references the company's 2023 annual report and 2024 Q1 report but does not contain the reports themselves or detailed financial data. The document is primarily an announcement of an investor presentation event rather than the presentation or report itself. Therefore, it fits best under Investor Presentation (IP) as it focuses on financial results and investor communication in a presentation format.
2024-05-17 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.